Capital Access Group

Capital Access Group advises companies on effective engagement with investors. Our experienced team offers market-leading access with hard-to-reach investors, including smaller institutions, pension funds and private client fund managers. These under-serviced investors are located not only in London but across the regions of the UK and Europe. We have an unrivalled knowledge of this extensive audience, to whom our published research is distributed, as well as to larger institutions. We offer this service as part of an integrated investor communications strategy to promote a company’s investment story.

Our clients, ranging from AIM to FTSE 100 companies, benefit from our professional, long-term relationships with investors. Not only do we identify and target investors, we contact them directly and relay their views back to clients with analysis, interpretation and advice. This ensures that our clients are in control of their investor engagement. The objective is to improve the reach and engagement with investors, which in turn strengthens the share price.

Sarah Godfrey
  • Sarah Godfrey

Beyond Barriers - EM opportunities in an era of trade tensions

Emerging and frontier markets are home to more than 85% of the world's population and generate over 40% of global GDP, yet make up only a small fraction of investors' portfolios. Allocations to these less developed – and generally faster-growing – economies have suffered in the era of tech-centred US exceptionalism, yet some of the world's most dominant technology companies are based in emerging markets. While Donald Trump's ‘Liberation Day' tariffs have sparked negative headlines regarding expo...

Colin Smith
  • Colin Smith

Polarean Imaging | Ascend representative agreement

Polarean has signed a Representative Agreement with Ascend Imaging LLC (Ascend) covering four specific US states. Under the agreement Ascend will act as a non-exclusive, independent manufacturer's representative supporting the promotion and sale of Polarean's Xenon MRI lung-imaging platform. Polarean has potential upside many times its current market capitalisation, we calculate, based on observable deal metrics and our NPV analysis, while the valuation is so low, it could attract take-over inte...

Sarah Godfrey
  • Sarah Godfrey

AEW UK REIT | Reinvesting for capital and income growth

AEW has reached the tenth anniversary of its IPO in May 2015, providing investors with a share price total return of c 120% since launch (c 80pp ahead of the AIC Property – UK Commercial sector average), as well as ranking highly in its peer group over shorter periods. The UK REIT is highly focused on value investment, acquiring mis-priced assets and then maximising income and unlocking capital upside through asset management initiatives. Since our last update, AEWU has sold the bulk of its larg...

Colin Smith
  • Colin Smith

Tullow Oil | Ghana licences extended to 2040

Tullow has announced the signature of a Memorandum of Understanding (MoU) for the extension of the licences covering its Jubilee and TEN fields in Ghana to 2040 on unchanged fiscal terms. These licence extensions unlock the potential for up to an additional 20 wells in the Jubilee field resulting in a potentially material increase in proven and probable reserves and an increase in gas sales on more secure terms. After allowing for the required additional investment, of up to US$2bn, we raise our...

Colin Smith
  • Colin Smith

TheraCryf (TCF) | FY25 results: expanded portfolio; focus on Ox-1

TheraCryf has released results for the year to March 2025 with the next 12-18 months set to be pivotal for the company as it focuses on advancing its Orexin-1 (Ox-1) programme while the Sulforaphane (SFX-01) programmes continue with third party funding. During FY25, the company acquired Chronos Therapeutics, making it a multi-compound drug developer, and raised a total of £5.2m, gross, funding the Ox-1 programme through to clinical readiness while extending TheraCryf's cash runway to 4Q 2026. Th...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch